Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

P.O. BOX 125, Stewartsville, United States

Pastandfuture Jul. 12 at 12:20 AM

$VYNE

0 · Reply

Pastandfuture Jul. 11 at 2:56 PM

$VYNE

0 · Reply

Wakaas93 Jul. 11 at 2:55 PM

$VYNE Merger vote is Thursday Followed by dividend payment following week Approval of merger should be straightforward Should hit $1 plus

0 · Reply

Wakaas93 Jul. 10 at 10:44 PM

$VYNE Loading up for the vote which should pass and then on to dividend Should hit $1

0 · Reply

J85bcfc Jul. 10 at 7:59 PM

$VYNE 😅 ‘corrupt’ CEO handed bears an ass bashin today. U would have to be an absolute idiot to short this now. Clear support range on a Friday afternoon, Every dip will get bought cus who doesn’t want free money with hat nice divi 💪💰

1 · Reply

PennySearch Jul. 10 at 6:26 PM

📊 Today's Highest Relative Volume $VYNE — 22.43x RVOL Move: -5% Volume: 15.5M (689.9K average) Market Cap: $10.7M $SNAL — 10.21x RVOL Move: +36% Volume: 2.2M (217.5K average) Market Cap: $40.9M $QADR — 7.35x RVOL Move: -0% Volume: 583.6K (79.4K average) Market Cap: $198.8M High relative volume highlights where market attention is concentrated. Which one are you watching? 👀 Not financial advice.

0 · Reply

Alboboy123 Jul. 10 at 5:57 PM

$VYNE analysis price targets at 2.10 dollars and .38 cents a share dividend. Currently .64 dollars. I dont see why the merger would fail. I am bullish on this stock.

1 · Reply

TheBullishOne007 Jul. 10 at 3:48 PM

$VYNE Hmm. 🤔

0 · Reply

Stumblingbuffalo Jul. 10 at 1:57 PM

$VYNE still have to approve on July 12th...

0 · Reply

MrTicker Jul. 10 at 1:55 PM

$VYNE The merger is expected to close on or about July 24

0 · Reply

VYNE Therapeutics declares special cash dividend with Yarrow Bioscience merger

Jul 10, 2026, 8:00 AM EDT - 1 day ago

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

May 15, 2026, 7:00 AM EDT - 2 months ago

VYNE Therapeutics Quarterly report: Q1 2026

Feb 27, 2026, 7:00 AM EST - 4 months ago

VYNE Therapeutics Annual report: Q4 2025

Dec 17, 2025, 8:30 AM EST - 7 months ago

VYNE Therapeutics Transcript: M&A Announcement

Dec 17, 2025, 8:30 AM EST - 7 months ago

VYNE Therapeutics Press release: M&A Announcement

2025-12-17T13:05:35.000Z - 7 months ago

VYNE Therapeutics, Yarrow Bioscience enter merger agreement

Dec 17, 2025, 8:00 AM EST - 7 months ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Nov 12, 2025, 7:00 AM EST - 8 months ago

VYNE Therapeutics Proxy statement: Proxy Filing

2025-11-06T13:11:20.000Z - 8 months ago

VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year

Nov 6, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Earnings release: Q3 2025

2025-08-14T12:05:20.000Z - 11 months ago

VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year

Aug 14, 2025, 8:00 AM EDT - 11 months ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 11 months ago

VYNE Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

VYNE Therapeutics Earnings release: Q2 2025

2025-07-31T00:36:00.000Z - 1 year ago

Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?

2025-07-30T23:45:15.000Z - 1 year ago

VYNE Therapeutics downgraded to Neutral from Buy at BTIG

2025-07-30T14:25:19.000Z - 1 year ago

VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss

2025-07-30T14:20:16.000Z - 1 year ago

VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2025-07-30T12:27:01.000Z - 1 year ago

VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint

Jul 30, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

2025-07-02T15:05:31.000Z - 1 year ago

H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update

2025-07-02T11:50:31.000Z - 1 year ago

VYNE Therapeutics provides program update on VYN202 following clinical hold

Jul 2, 2025, 7:45 AM EDT - 1 year ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

2025-05-08T12:40:54.000Z - 1 year ago

VYNE Therapeutics reports Q1 EPS (20c) vs (15c) last year

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Earnings release: Q1 2025

2025-04-25T13:15:22.000Z - 1 year ago

VYNE Therapeutics price target lowered to $4.50 from $5.75 at H.C. Wainwright

2025-04-25T12:07:47.000Z - 1 year ago

VYNE Therapeutics announces FDA placed clinical hold on study on VYN202

Apr 25, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 27, 2025, 11:00 AM EDT - 1 year ago

VYNE Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

2025-03-06T13:06:55.000Z - 1 year ago

VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year

Mar 6, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Annual report: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 11:10 AM EST - 1 year ago

VYNE Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in March Investor Conferences

2025-02-19T13:11:11.000Z - 1 year ago

VYNE Therapeutics announces dosing of first patient in Phase 1b trial of VYN202

Feb 19, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

2025-01-06T12:35:20.000Z - 1 year ago

VYNE Therapeutics completes enrollment in Phase 2b trial on VYN201

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Nov 12, 2024, 7:00 AM EST - 1 year ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q3 2024

Sep 17, 2024, 8:30 AM EDT - 1 year ago

VYNE Therapeutics Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q2 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 2 years ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 2 years ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 1, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Registration statement: Registration Filing

Feb 29, 2024, 8:00 AM EST - 2 years ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Annual report: Q4 2023

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Earnings release: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Registration statement: Registration Filing

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 9, 2023, 1:30 PM EST - 2 years ago

VYNE Therapeutics Transcript: R&D Day 2023

Nov 9, 2023, 1:30 PM EST - 2 years ago

VYNE Therapeutics Slides: FY 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q2 2023

May 18, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 3 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q1 2023

May 1, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Annual report: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Earnings release: Q4 2022

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Pastandfuture Jul. 12 at 12:20 AM

$VYNE

0 · Reply

Pastandfuture Jul. 11 at 2:56 PM

$VYNE

0 · Reply

Wakaas93 Jul. 11 at 2:55 PM

$VYNE Merger vote is Thursday Followed by dividend payment following week Approval of merger should be straightforward Should hit $1 plus

0 · Reply

Wakaas93 Jul. 10 at 10:44 PM

$VYNE Loading up for the vote which should pass and then on to dividend Should hit $1

0 · Reply

J85bcfc Jul. 10 at 7:59 PM

1 · Reply

PennySearch Jul. 10 at 6:26 PM

0 · Reply

Alboboy123 Jul. 10 at 5:57 PM

$VYNE analysis price targets at 2.10 dollars and .38 cents a share dividend. Currently .64 dollars. I dont see why the merger would fail. I am bullish on this stock.

1 · Reply

TheBullishOne007 Jul. 10 at 3:48 PM

$VYNE Hmm. 🤔

0 · Reply

Stumblingbuffalo Jul. 10 at 1:57 PM

$VYNE still have to approve on July 12th...

0 · Reply

MrTicker Jul. 10 at 1:55 PM

$VYNE The merger is expected to close on or about July 24

0 · Reply

MrTicker Jul. 10 at 1:55 PM

$VYNE VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger MT NEWSWIRES 7:33 AM ET 7/10/2026 The dividend will be payable to shareholders and warrant holders of record as of July 22, with funds expected to be paid to VYNE's transfer agent on July 23

0 · Reply

joe77w Jul. 10 at 1:07 PM

$VYNE pps will be reduced by .38 USD when dividend Paid therefore I dont see why holding stock unless you would remain shareholder in Yarrow. Vyne Shareholders heavily diluted with this RM. I was thinking in .48 divy but my assumption wrong. Glty

0 · Reply

OpenOutcrier Jul. 10 at 12:39 PM

$VYNE (-7.5% pre) VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience https://ooc.bz/l/107456

0 · Reply

FshOn Jul. 10 at 12:32 PM

$VYNE buying 10K shares and holding for big dividends payout

1 · Reply

Stumblingbuffalo Jul. 10 at 12:25 PM

$VYNE decalring a special divy only drops the stock on divy date... seen this many times good luck!

0 · Reply

Stumblingbuffalo Jul. 10 at 12:20 PM

$VYNE close the gap to .4 cents and i might think about it, 😄 🤣 😂 😆

0 · Reply

buttermeupalready Jul. 10 at 12:19 PM

$VYNE longs will be sorry for meddling with power they dont understand

0 · Reply

Stumblingbuffalo Jul. 10 at 12:13 PM

$VYNE well that age well, f your dividen... 😄 🤣 😂 😆 i guess nobodys buying it, literally!

0 · Reply

Dl71174 Jul. 10 at 12:12 PM

$VYNE 11,000 watchers and no one contributes on board. Well that's not a good sign as I see the company also quite during past few months

1 · Reply

Stock_Catcher Jul. 10 at 12:01 PM

$VYNE VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

0 · Reply

hiTHit Jul. 2 at 6:03 PM

$VYNE The CEO tells the shareholders: "I don't recall promising you that the share price would go up. Now I'm telling you that the price isn't going to go up, and if you aren't happy about it, sell your holdings immediately and get the hell out of here."

1 · Reply

Dimitri_Prints Jun. 28 at 12:25 PM

$VYNE getting it for the low tomorrow

0 · Reply

Market Cap	21.27M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,645.61%
Debt to Equity Ratio	0.00

Volume	16,093,100
Avg Vol	499,352
Day's Range	N/A - N/A
Shares Out	33.35M
Stochastic %K	31%
Beta	2.00
Analysts	Sell
Price Target	$2.00